Skip to main content
. 2021 Oct 19;8(24):2102051. doi: 10.1002/advs.202102051

Figure 13.

Figure 13

The HEK‐293T cell‐derived exosome was engineered with TLS11a aptamer‐modified TDNs to deliver CRISPR/Cas9 RNP for HCC therapy. A) Structure of TDN1‐EV loaded with CRISPR RNP targeting the WNT10B gene. B) Tumor‐targeting efficiency showed by fluorescent biodistribution image after 12 h of intravenous injection. T, tumor; H, heart; Li, liver; S, spleen; Lu, lung; K, kidney. C) The indel analysis of the HepG2 cells treated by different Cas9/sgWNT10B vectors. D) Quantification of organoid killing with different Cas9/sgWNT10B vectors. *p < 0.05, **p < 0.01, (one‐tailed t‐test). ns: p > 0.05. E) Representative images of xenograft tumors harvested from HCC mouse models. Reproduced with permission.[ 112 ] Copyright 2020, Oxford University Press.